The OLR1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, providing a loss-of-function model for the human OLR1 gene. This heterogeneous pool of edited cells bears targeted disruption of the LOX-1 scavenger receptor gene, enabling robust analysis of OLR1-mediated signaling and functions without clonal bias.
Raji is an EBV-positive Burkitt lymphoma B lymphocyte line widely used to model B cell malignancies, immunoglobulin production, and immune functions. These suspension cells retain active NF-??B signaling and surface immunoglobulin expression, providing a relevant context to study LOX-1 in lymphocyte biology, including adhesion, scavenger activity, and oxidative stress responses.
OLR1 encodes LOX-1, the primary receptor for oxidized LDL (oxLDL) on endothelial and immune cells. LOX-1 binding by oxLDL, HSP60/70, C-reactive protein, or apoptotic cells activates NOX2, p38 MAPK, JNK, PKC, and RhoA, leading to NF-??B p65 nuclear translocation and upregulation of adhesion molecules (VCAM-1, ICAM-1), MCP-1, NADPH oxidase, and MMPs. Upstream, TNF-??, IL-1??, angiotensin II, and shear stress induce OLR1 via NF-??B and AP-1. LOX-1 signaling promotes ROS generation, NLRP3 inflammasome activation, and caspase-3-dependent apoptosis, with interacting partners Rac1 and p66Shc modulating these pathways.
In Raji cells, OLR1 knockout disrupts LOX-1-dependent adhesion and oxLDL scavenging, potentially impairing NF-??B activation and inflammatory responses. This model facilitates dissection of LOX-1??s role in B cell malignancies, lipid uptake, and antigen presentation, and provides a clean system to study alternative oxLDL receptors and signaling crosstalk.
Applications include Western blotting and RT-qPCR for knockout validation, flow cytometry for surface LOX-1, oxLDL binding/uptake assays, NF-??B reporter and adhesion assays, apoptosis (Annexin V/PI) analysis, cytokine ELISA, and ROS measurement. This product is ideal for studying atherosclerosis, inflammation, hypertension, and lymphoma, and for drug target validation or LOX-1 inhibitor screening. For more information, please contact Ascent Research.
